Diverging the anthracycline class of anti-cancer drugs for

2 **superior survival of acute myeloid leukemia patients**

3

Xiaohang Qiao,^{1,2,*,†} Sabina Y. van der Zanden,^{3,*} Xiaoyang Li,^{4,*} Minkang Tan,³ Yunxiang
Zhang,⁴ Ji-Ying Song,⁶ Merle A. van Gelder,³ Feija L. Hamoen,³ Lennert Janssen,³ Charlotte
L. Zuur,^{1,2} Baoxu Pang,³ Olaf van Tellingen,⁵ Junmin Li,^{4,†} and Jacques Neefjes^{3,†}

- 7
- ¹Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands;
- 9 ²Department of Head and Neck Oncology and Surgery, The Netherlands Cancer Institute, Amsterdam, The
- 10 Netherlands;
- ³Department of Cell and Chemical Biology, ONCODE Institute, Leiden University Medical Center, Leiden, The
 Netherlands;
- ⁴Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for
- 14 Translational Medicine, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine,
- 15 Shanghai, China;
- ⁵Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands;
- ⁶Division of Experimental Animal Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands;
- 18 *These authors contributed equally to this work.
- 19
- 20 [†]Correspondence: email: x.qiao@nki.nl; drlijunmin@126.com; j.j.c.neefjes@lumc.nl
- 21

22 Key words:

- 23 Anthracycline, Doxorubicin, Aclarubicin, Acute Myeloid Leukemia, Cardiotoxicity, Histone
- 24 Eviction, Bio-distribution, Cross-resistance

25 Abstract

26 The efficacy of anthracycline-based chemotherapeutics, which include doxorubicin and its 27 structural relatives daunorubicin and idarubicin, remains almost unmatched in oncology, 28 despite a side effect profile including cumulative dose-dependent cardiotoxicity, therapy-29 related malignancies and infertility. Detoxification of anthracyclines while preserving their 30 anti-neoplastic effects is arguably a major unmet need in modern oncology, as cardiovascular 31 complications that limit anti-cancer treatment are now a leading cause of morbidity and 32 mortality among the 17 million cancer survivors in the U.S.. To address this, we examined 33 different clinically relevant anthracycline drugs with respect to a series of features including 34 mode of action (chromatin and DNA damage), bio-distribution, anti-tumor efficacy and 35 cardiotoxicity in pre-clinical models and patients. We show that different anthracycline drugs 36 have surprisingly individual efficacy and toxicity profiles. In particular, aclarubicin stands 37 out in pre-clinical models and clinical trials as it potently kills cancer cells, does not induce 38 therapy-related malignancies or cardiotoxicity, and can be safely administered even after a 39 maximum cumulative dose of either ida- or doxorubicin has been reached. Retrospective 40 analysis of aclarubicin used in second-line treatment of relapsed/refractory AML patients 41 showed similar survival effects to its use in first line, leading to an almost 25% increase in 5-42 year overall survival. Considering individual anthracyclines as different drugs provides new 43 treatment options that strongly improve survival of cancer patients while limiting the toxic 44 side-effects.

45

46 Introduction

Most anthracyclines function as poisons of the enzyme topoisomerase II (TopoII) that trap it
on chromatin and thus induce DNA double-strand breaks (DSBs) [1]. In addition, these drugs
also evict histones from defined genomic areas, which results in delayed DNA damage repair

2

50 and epigenetic and transcriptomic alterations, collectively termed chromatin damage [2-4]. 51 Histone eviction appears to be a major cytotoxic activity of anthracyclines [5]. TopoII poisons, like etoposide, that only generate DSBs are considerably less effective in cancer 52 53 treatment [2, 6], and also less toxic [5, 7]. On the contrary, aclarubicin only induces histone 54 eviction and is highly effective in treating *de novo* acute myeloid leukemia (AML) [5]. 55 Hence, DNA damage appears not to be a prerequisite for effective anti-cancer activities. Removing DNA damage from chromatin damage activity mitigates cardiotoxicity and 56 57 therapy-related tumorigenesis of anthracyclines, without hampering their anti-cancer effect [5]. Clinical application of detoxified anthracyclines will confer major benefits in cancer 58 59 therapy, expanding treatment options for patients with comorbidities including older adults 60 [8] and reducing late effects, particularly for pediatric patients [9]. Detoxified anthracyclines 61 would enable chronic treatment of cancer, while the current toxic anthracyclines only allow 62 for limited treatment due to cumulative dose-dependent cardiotoxicity risk. Here, we systematically evaluated anthracycline drugs currently used in clinic against a series of key 63 64 features to determine whether they differ in terms of anti-neoplastic potency, site of action 65 and toxicity profiles. We identified aclarubicin, currently used only in Asia for AML patients 66 with high comorbidity indices, as an anthracycline variant that lacks cardiotoxicity side 67 effects and can be used after maximum dose of doxo- or ida in mice and men. Aclarubicin-68 based therapy increases the overall survival of relapsed/refractory AML patients by almost 69 25%. These data illustrate how aclarubicin can transform leukemia treatment for children. 70 unfit adults and relapsed/refractory AML patients that currently have a poor prognosis, 71 addressing a major unmet need in current oncology practice.

72

73 Materials and methods

74 **Reagents**

Doxorubicin and etoposide were purchased from Pharmachemie (The Netherlands), daunorubicin was obtained from Sanofi-Aventis and epirubicin was obtained from Accord Healthcare Limited (UK), idarubicin was obtained from Pfizer and Santa Cruz Biotechnology (sc-204774). Aclarubicin for in vivo mouse experiments was obtained from Shenzhen Main Luck Pharmaceuticals Inc. Aclarubicin (for in vitro experiments, sc-200160) and amrubicin (sc-207289) were obtained from Santa Cruz Biotechnology.

81

82 Cell culture

K562, MM6, MOLM13, MV4:11, and U937 and THP-1 were cultured in RPMI-1640
medium supplemented with 8% fetal calf serum (FCS). OCI-AML2 and OCI-AML3 and
OCI-AML4 were cultured in Iscove's Modified Dulbecco's medium (IMDM) supplemented
with 8% FCS and glutamine. MelJuSo cells were maintained in IMDM supplemented with
8% FCS. All cell lines were maintained in a humidified atmosphere of 5% CO₂ at 37 °C,
regularly tested for the absence of mycoplasma and STR profile identified.

89

90 Cell line construction

91 For endogenous tagged GFP-H2B K562 cells, mScarlet was swapped for GFP in the 92 homology repair construct using NheI and BgIII and cells were generated as described [5]. 93 Co-transfection into K562 cells was done by electroporation using Lonza SF cell line kit. 94 ABCB1 overexpressing K562 cells were generated as described [10]. Endogenous tagged 95 3×Flag-TopoIIα K562 cell line was generated using HR-3×Flag construct designed at least 40 96 base pairs up and downstream of the genomic TopoII α stop codon. The gRNA target 97 sequence was designed using the ZANG Lab CRISPR tool (http://crispr.mit.edu/) and cloned for HR 5'-98 into the pX330 vector. Primers the construct: used 99 CACCGATGATCTGTTTTAAAATGTG-3' and 5'-AAACCACATTTTAAAAACAGATC

4

100	ATC-3'.	Co-transfection	of ssDNA	oligo and	CRISPR plasmic	l (pX459)	into K562	cells was
-----	---------	-----------------	----------	-----------	----------------	-----------	-----------	-----------

101 performed by electroporation using Lonza SF cell line kit. Primers used for genotyping:

102 forward primer: 5'-TAAGCAGAATTCATGCCACTTATTTGGGCAAT-3' and reverse

- 103 primer: 5'-TGCTTAAAGCTTTGCCCATGAGATGGTCACTA-3'.
- 104

105 DNA damage assessed by Western blot and CFGE

- 106 After 2-hour drug treatment of indicated drugs at 5μ M, cells were washed with PBS. WB and
- 107 CFGE were performed as described [11]. Images were quantified with ImageJ.

108

Fractionation assay

Endogenously tagged GFP-H2B cells (1×10^6) were pre-incubated with protease inhibitor 110 111 cocktail (P1860-1ML, Sigma-Aldrich) for 1 hour followed by 3-hour treatment with 10 µM 112 of the indicated drugs. Cells were dissolved in lysis buffer (50mM Tris-HCl pH 8.0, 150 mM 113 NaCl, 5 mM MgCl₂, 0.5% NP40, 2.5% glycerol supplemented with protease inhibitors, 10 114 mM NMM) for 5 min on ice, and then centrifuged for 10 min at 15,000 g at 4°C. Both 115 nucleus (pellet) and cytosol (supernatant) were washed once and submitted for Western Blot 116 analysis. Primary antibodies used for detection: GFP (1:1000) [12], Lamin B1 (1:1000, 117 12987-I-AP, Proteintech), Calnexin (1:1000, C5C9, Cell signaling).

118

119 **Time-lapse confocal microscopy**

For time-lapse confocal imaging, MelJuSo cells were seeded in 35-mm bottom petri dish
(Poly-dlysin Coated, MatTek Corporation), transfected with TopoIIα-GFP construct
(effectene, Qiagen) and imaged upon treatment with the indicated drugs [2]. Leica SP8
confocal microscope system, 63×lens, equipped with a climate chamber was used. TopoIIαGFP distribution was quantified using Leica Application Suite X software.

125

126 Short-term cell viability assay

Twenty-four hours after seeding into 96-well plates, cells were treated with indicated drugs for 2 hours at physiologically relevant concentrations [2]. Subsequently, drugs were removed by extensive washing, and cells were cultured for an additional 72 hours. Cell viability was measured using the CellTiter-Blue viability assay (Promega). Survival was normalized to the untreated control samples after correction for the background signal.

132

133 ChIP-seq

Endogenous tagged 3×Flag-TopoIIα K562 cells were treated with 10 μM of indicated drugs
for 4 hours. Cells were fixed and processed as described [3, 13]. ChIP was done with antiFlag M2 (F3165, Sigma), followed by sequencing on an Illumina Hiseq2000 platform
(Genome Sequencing Service Center of Stanford Center for Genomics and Personalized
Medicine Sequencing Center).

139 ChIP-seq data were processed identically using the ENCODE Data Coordination Center 140 (DCC) ChIP-seq pipeline (https://github.com/ENCODE-DCC/chip-seq-pipeline2) (v1.9.0). 141 Briefly, the ChIP-seq reads were aligned to the human reference genome (GRCh37/hg19) 142 using Bowtie2 [14]. Duplicate reads were removed using Picard MarkDuplicates 143 (RRID:SCR_006525). Peaks of each sample were called against the whole-cell lysates 144 replicates using SPP [15] with the parameters '-npeak 300000 -speak 155 -fdr 0.01'. The

145	blacklisted regions described by ENCODE were discarded [16]. Reproducible peaks were
146	intersected from two biological replicates and annotated with epigenomic signatures of K562,
147	downloaded from the Roadmap Epigenomics Project [17]. Normalized TopoIIa binding
148	affinity matrix: consensus peaks by samples, principle component analysis and differential
149	binding affinity analysis were performed using the R package DiffBind [18].

150

151 ATAC-seq

K562 cells were treated with 10 μM of indicated drugs for 4 hours. Cells were fixed and
processed as described [19, 20]. DNA was processed using a customized library preparation
method for ATAC-seq and was sequenced using an Illumina HiSeq4000 platform.

155 ATAC-seq data were processed identically using the ENCODE Data Coordination Center 156 (DCC) ATAC-seq pipeline (https://github.com/ENCODE-DCC/atac-seq-pipeline) (v1.10.0). 157 Briefly, the ATAC-seq reads were aligned to the human reference genome (GRCh37/hg19) 158 using Bowtie2 [14]. Duplicate reads were removed using Picard MarkDuplicates 159 (RRID:SCR_006525). Peaks were called using MACS2 [21] with the setting of '-p 0.01 --160 shift -75 --extsize 150 --nomodel -B --SPMR --keep-dup all', then followed by blacklisted 161 regions filtering described by ENCODE [16]. Reproducible peaks were identified from two 162 biological replicates and annotated with epigenomic signatures of K562, downloaded from 163 the Roadmap Epigenomics Project [17]. ATAC-seq signal tracks for all the samples were 164 generated by bedtools with the command 'bedtools genomecov -scale' using the read count 165 per million (CPM) normalization and convert to bigwig files using bedGraphToBigWig. 166 Normalized ATAC-seq read density matrix: consensus peaks by samples, principle 167 component analysis and differential chromatin accessibility analysis were performed using 168 the R package DiffBind [18].

169

170 The bio-distribution of anthracyclines in mice

171 FVB/NRj mice ordered from Janvier Labs (Le Genest-Saint-Isle, France) were housed in 172 individually ventilated cages under specific pathogen-free conditions in the animal facility of 173 the NKI (Amsterdam, The Netherlands). All mouse experiments were approved by the 174 Animal Ethics Committee of the NKI and were performed according to institutional and 175 national guidelines. Male mice (8-week old) were i.v. injected with Doxo, Acla, Amr, Epi or 176 Ida at 5 mg/kg (n = 5 per group). Four hours post injection, animals were sacrificed, and plasma, heart, lung, liver, kidney, spleen, brain, thymus, axillary and inguinal lymph nodes, 177 178 and testis+epididymis were collected. Hearts were cut into two pieces with coronal section. 179 One piece was fixed in EAF fixative (ethanol/acetic acid/formaldehyde/saline, 40:5:10:45 180 v/v/v/v) and processed for Phospho-H2AX (Ser139) IHC (1:100, #2577, Cell Signaling). The 181 other half of the heart and the rest of organs were weighted, frozen and analyzed by LC-182 MS/MS [5].

183

The cardiotoxicity of anthracyclines in mice

185 FVB/NRj mice (10-11-week old) were i.v. injected with 5 mg/kg of Doxo, 5 mg/kg of Acla, 186 or 5 ml/kg of saline every 2 weeks for 4 times. After 4-week interval, the animals were i.v. 187 injected with 5 mg/kg of indicated drug or 5 ml/kg of saline every 2 weeks for another 4 188 times. The mice were monitored every other day. When body weight loss was more than 189 20%, or circulation failure occurred, animal was euthanized by CO_2 . Subsequently, full body 190 anatomy was performed. All organs were collected, fixed in EAF fixative and embedded in 191 paraffin. Sections were cut at 2 μ m from the paraffin blocks and stained with hematoxylin 192 and 4 µm for immunohistochemistry of Desmin (1:200, M0760, and eosin, 193 DakoCytomation), Vimentin (1:100, #5741, Cell Signaling), or Periostin (1:100, ab215199, 194 Abcam). Pathology slides were reviewed twice by an expert mouse pathologist who was

blind to the treatment. Incidence rate (IR = [number of mice with the specific side effect over a time period]/[sum of mice \times time at risk during the same time period]) and cumulative incidence (CI = [number of mice with specific side effect at end time point]/[total number of mice at start]) were calculated for indicated side effects.

199

200 r/rAML patients

201 Patients with refractory or relapse AML treated between July 2012 and July 2022 at Ruijin 202 hospital, China were enrolled in this retrospective study. Some patients participated in trail 203 ChiCTR-OPC-14005712, ChiCTR-OPC-15006896, ChiCTR-IIR-16008809, ChiCTR-OIC-204 16008952, ChiCTR-IIR-16008962 and ChiCTR-IIR-17011677. This study was approved by 205 the ethics committee of Ruijin Hospital, all patients provided written informed consent. 206 Cytogenetic risk was classified according to the modified Southwest Oncology Group criteria 207 [22], and integrated risk was classified as described [23]. The treatment details were decribed 208 in supplemental materials and methods. The baseline characteristics and clinical outcomes of 209 the patients are summarized in supplemental Tables 1 and 2, respectively.

210 Cytogenetic risk was classified according to the modified Southwest Oncology Group 211 criteria [22]: (1) favorable risk, including t(8;21) and inv(16) or t(16;16)(p13;q22); (2) 212 unfavorable risk, including del(5q) or monosomy 5, monosomy 7 or del(7q), abnormal 3q, 213 9q, 11q, 21q, or 17p, t(6;9), t(9;22), and complex karyotypes (three or more unrelated 214 chromosomes abnormal); and (3) intermediate risk, including normal karyotypes and all other 215 anomalies. FLT3 internal tandem duplication and mutations in CEBPA, NPM1 and IDH1/2 216 were tested. Integrated risk was classified as described [23]. CR was defined as bone marrow 217 blasts <5%, absolute neutrophil count $\geq 1 \times 10^{9}$ /L, and platelet count $\geq 100 \times 10^{9}$ /L, and absence 218 of extramedullary disease. Partial remission was defined as having <15% (and a 50% 219 decrease in bone marrow blasts) but >5% blasts or with <5% blasts but not reaching the CR

criteria for blood cell count or clinical manifestation. The baseline characteristics and clinical
outcomes of the patients are summarized in supplemental Tables 1 and 2, respectively.

222

223 **AML treatments**

CAG patients were treated with $15\Box 25 \text{ mg/m}^2$ of Ara-C (cytarabine) injected s.c. every 12 h 224 on days $1 \Box 14$, 20 mg/d of Acla infused i.v. on days $1 \Box 4$, and 200 μ g/m² of granulocyte 225 stimulating factor (G-CSF) administered s.c. daily on days 1 14. G-CSF was reduced, or 226 temporarily stopped when neutrophilia was $>5 \times 10^{9}$ /L. IA patients were treated with 6210 227 mg/m^2 of Ida infused i.v. on days $1\Box 3$ and $100\Box 200 mg/m^2$ of Ara-C on days $1\Box 7$. VA 228 patients were injected with 75 mg/m² of azacitidine s.c. daily on days $1\Box 7$, and administered 229 with venetoclax orally, once daily. The dose of venetoclax was 100 mg on day 1 and 200 mg 230 231 on day 2; and 400 mg on days $3 \square 28$. In all subsequent 28-day cycles, the dose of venetoclax 232 was initiated at 400 mg daily. The other induction chemotherapy for r/rAML patients 233 included IA, DA, FLAG, CLAAG and CHA regimens. For patients treated with DA regimen, 20 mg/m² of decitabine was administered i.v. daily on days $1\Box 5$, and 1 g/m^2 of Ara-C was 234 235 injected every 12 hours on days 6 7. For patients treated with FLAG regimen, fludarabine was infused i.v. at 30 mg/m² on days $2\square 6$; 4 hours after fludarabine infusion, Ara-C was 236 injected i.v. at 1.5 $\mathbb{E}2$ g/m² over 3 hours on days $2\square 6$; G-CSF was administered at 5 µg/kg s.c. 237 on days 115; additional G-CSF may be administered since 7 days after the end of 238 239 chemotherapy until WBC count >500/uL. For patients >60-year-old, the dose may be reduced to 20 mg/m² for fludarabine and $0.5 \square 1$ g/m² for cytarabine. For patients treated with CLAAG 240 regimen, 5 mg/m² of cladribine was infused i.v. over 2 hours on days $1 \Box 5$; 15 mg/m² of Ara-241 242 C was injected s.c. every 12 hours on days $1\Box 10$; trans retinoic acid (ATRA) was administered orally at 45 mg/m² on days $4\Box 6$, then at 15 mg/m² on days $7\Box 20$; 300 µg G-243 CSF was injected s.c. on day 0. For patients treated with CHA regimen, 5 mg/m² of 244

cladribine was infused i.v. over 2 hours on days $1\Box 5$; 2 mg/m² of homoharringtonine was infused i.v. over 2 hours on days $1\Box 5$; 1 g/m² of Ara-C was injected 2 hours after cladribine on days $1\Box 5$.

248

249 Statistical analyses

Results are shown as mean \pm SEM or mean \pm SD. Statistical analysis was performed using Prism unless otherwise specified. All the in vitro experiments were performed with a minimum of three independent trials with the exception of ChIP-seq and ATAC-seq which were in biological duplicates. All the animals of mouse experiments are shown in the dot plots. Statistical tests are indicated in each figure legend.

255

256 **Results**

257 Mechanisms of action and cross-resistance of anthracyclines

258 To assess whether the various clinically administered anthracyclines (Fig. 1A) differ in their 259 DNA- and chromatin-damaging activities, as well as cross-resistance, we exposed AML cell 260 line THP1 at a clinically relevant dose for 2 hours followed by further culturing to mimic the 261 pharmacokinetics in patients [24]. DNA damage was assessed by constant-field gel 262 electrophoresis (CFGE) [11] and phosphorylation of H2AX at Ser139 (yH2AX) [25] as 263 detected by Western blotting. Doxorubicin (Doxo), daunorubicin (Daun), epirubicin (Epi), 264 idarubicin (Ida), and amrubicin (Amr) all induced DSBs, unlike aclarubicin (Acla) (Fig. 1B-265 E). Next, chromatin damage as the result of histone eviction was visualized by a fractionation 266 assay using K562 cells with endogenously tagged GFP-H2B. Except for Amr, all the tested 267 anthracyclines induced histone release from nucleus and accumulation in cytosol (Fig. 1F,G; 268 Fig. S1A). Furthermore, all histone-evicting anthracyclines were able to redistribute GFP-269 TopoII α on chromatin (Fig. S1B,C). Cytotoxicity assays revealed poor anti-cancer activity

for the DNA-damaging analog Amr, while the other analogs bearing chromatin-damaging
activity were effective in eliminating various myeloid leukemia cell lines (Fig. 1H).

272 In addition to treatment-limiting cardiotoxicity, drug resistance could also limit the effect 273 of anthracycline drugs. ABCB1 is a major drug efflux transporter contributing to 274 anthracycline resistance [26]. We generated a Doxo-resistant leukemia cell line by 275 overexpressing ABCB1 [10] and tested its sensitivity to other anthracyclines (Fig. 1I-K; Fig. 276 S1D). The ABCB1-overexpressing cells acquired resistance to Doxo, Daun, Epi and Amr, but 277 failed to export Ida and Acla efficiently (Fig. 1J,K). These data together indicate that 278 clinically relevant anthracyclines should be considered as distinct drugs with unique features 279 and different efficiencies. Evicting histories and relocalizing TopoII α while not inducing 280 DSBs, as in the case of Acla, apparently suffices for efficient cytotoxicity.

281

282 Epigenetic selectivity of TopoIIa redistribution and histone eviction of

283 anthracyclines

284 Anthracyclines poison TopoII by disrupting its interface with DNA by their sugar moieties 285 and the cyclohexene ring [27]. However, the anthracycline-specific redistribution of TopoII 286 and its association with histone eviction have not been characterized. We addressed this in 287 K562 cells whose epigenomic information has been extensively profiled by ENCODE 288 consortium [28]. Chromatin immunoprecipitation followed by deep sequencing (ChIP-seq) 289 against endogenously tagged TopoIIa was performed 4 hours after anthracycline exposure in 290 independent duplicate experiments (Fig. S2A). The resulting ChIP-seq profiles analyzed by 291 principal component analysis (PCA) suggested that all histone-evicting anthracyclines cause 292 extensive and drug-specific TopoII α redistribution as compared to untreated or Amr-treated 293 cells (Fig. 2A,B). To characterize this drug-specific TopoIIa redistribution, we coupled the 294 ChIP-seq data to the epigenetic information of ENCODE (Fig. 2C). With the same sugar

295 moiety and cyclohexane (Fig. 1A), Daun and Doxo (also labeled as hydroxyDaun) depleted 296 TopoII α from active chromatin regions, like DNase I hypersensitive regions (DHS), H3K4me1, H3K4me2, H3K4me3, H3K9ac, H3K27ac, H3K79me2 and H2A.Z [29]. Instead. 297 298 TopoIIα was trapped in compact chromatin regions marked by H3K27me3 [29], H3K9me1 299 [30] and H3K9me3 [31] (Fig. 2C). Ida and Acla depleted TopoIIa from broader chromatin 300 states, except for H3K9me3 [31], H3K27me3 [29] and H3K36me3 [31] decorated regions 301 (Fig. 2C). Epi, with an epimerizing hydroxyl group at the sugar moiety (Fig. 1A), further 302 depleted TopoIIa from H3K36me3 [31] modified regions (Fig. 2C). It is worth noting that the 303 redistribution of TopoII α at regions with unknown epigenetic features was increased for all 304 drugs, except for Amr (Fig. 2C).

305 While the TopoIIa redistribution showed drug specificity, we continued to identify 306 histone eviction preferences of each anthracycline using transposase-accessible chromatin 307 with sequencing (ATAC-seq) [19] in K562 cells (Fig. 2D). In line with its lack of chromatin-308 damaging activity (Fig. 1F,G), Amr failed to induce de novo open chromatin and could 309 therefore be found close to untreated cells in PCA plot (Fig. 2E). Similar to the TopoII α 310 redistribution pattern, the other tested anthracyclines evicted histones mostly from open 311 chromatin regions, once again exhibiting distinct preferences (Fig. 2F). As histone 312 modifications are required for recruitment of TopoIIa to DNA [32], selective eviction of 313 histones from open chromatin regions may contribute to the observed depletion of TopoIIa 314 from the same regions. Based on the comparative analysis of TopoIIa ChIP-seq and the 315 ATAC-seq experiments, we observed that regions identified by both ATAC-seq and TopoII α 316 ChIP-seq were greatly decreased by histone-evicting anthracyclines (Fig. 2G,H; Fig. S2B). 317 Nonetheless, outside of overlapping regions, TopoIIa redistribution and *de novo* accessible 318 chromatin were usually not associated with each other, indicating that these may constitute 319 two independent effects of anthracyclines (Fig. S2B). Thus, integration of TopoIIa ChIP-seq

13

and ATAC-seq revealed the connection between histone eviction and TopoIIα depletion in
transcriptionally active regions, as well as selective impact of each analog on the epigenetic
landscape. Each clinically used anthracycline has individual genomic preferences, which may
define drugs with different specificity.

324

325 **Bio-distribution of anthracyclines**

326 Acla is effective in eliminating a large variety of cancer cells in tissue culture [5]. However, it 327 is mainly used in treating AML and is less effective against solid tumors [33, 34]. This could 328 be the result of differences in biodistribution of anthracyclines. To test this, we performed a 329 comprehensive pharmacokinetic study for Acla and the other clinically used anthracyclines in 330 mice. Four hours post iv injection of a clinically relevant dose of indicated drug at 5 mg/kg 331 [35], Doxo, Epi and Ida showed similar bio-distribution patterns across different organs (Fig. 332 3A; Fig. S3A). Amr had a similar tissue distribution as Doxo, but showed reduced 333 distribution to lung, kidneys, and heart. Brain tissue was poorly penetrated by all drugs (Fig. 334 3A; Fig. S3A). A notable exception was Acla, which accumulated in lymphoid organs 335 (spleen, thymus and lymph nodes) but poorly distributed to other organs (Fig. 3A; Fig. S3A). 336 This might be an explanation why Acla is ineffective in treating solid tumors, as opposed to 337 hematologic tumors.

We further evaluated DNA damage in the heart in response to drug exposure. While
Doxo, Epi and Ida incited persistent DNA damage in the heart, the hearts of Acla- and Amrtreated mice did not show any γH2AX signals 4 hours after drug administration (Fig. 3B; Fig.
S3B), in line with poor tissue penetration of Acla and Amr and the fact that Acla does not
induce DNA damage at all.

343

Acla is safe and well tolerated following Doxo treatment

345 Doxo, Daun, Ida and Epi all induce cumulative dose-dependent cardiotoxicity, which limits 346 patient treatment to only few courses. Since Acla treatment is not associated with cardiotoxicity [5], we reasoned that it could be safe to apply this drug to mice following 347 348 treatment with cardiotoxic anthracyclines. To test this, Acla was administered to mice after 349 half-maximum cumulative dose of Doxo (Fig. 4A) and followed over time. Cardiotoxicity 350 induced by Doxo caused cardiac hypertrophy and remodeling that presented as thrombus 351 formation in the left atrium and auricle of the heart accompanied by inflammation, fibrosis 352 and calcification [5, 36] (Fig. 4B; Fig. S4A). Further staining for profibrotic proteins 353 vimentin [37] and periostin [38], and cytoskeletal protein desmin [39], revealed impairment 354 of myocytes and fibrosis in the stroma (Fig. 4C-H; Fig. S4B-F). With impaired cardiac 355 function, Doxo-treated mice died from circulation failure (Fig. 4I).

356 Reflecting clinical observations [40] and our prior work [5], the incidence, latency and 357 histopathological alterations of Doxo-induced cardiotoxicity developed in a dose-dependent 358 manner (Fig. 4A, D-C vs D-D), whereas eight courses of Acla treatment showed no 359 abnormalities in the heart (Fig. 4F-K; Fig. S4, A-A vs C-C/D-C/D-D). More importantly, Acla treatment after half-maximum cumulative dose of Doxo did not aggravate cardiotoxicity 360 361 (Fig. 4; Fig. S4, D-A vs D-D). Similarly, pre-treatment with Acla did not make mice more 362 susceptible to Doxo-induced cardiotoxicity (Fig. 4; Fig. S4, A-D vs D-C/D-D). Hence, Acla 363 is safe and well tolerated following Doxo treatment in this model system. Considering limited 364 cardiotoxicity, little cross-resistance and differences in epigenomic specificities between 365 anthracyclines, Acla would be predicted to act as an independent drug in salvage 366 relapsed/refractory AML (r/rAML) patients who have already received the maximum 367 cumulative dose of cardiotoxic anthracyclines. Such systematic studies have not been 368 reported.

369

370 CAG strongly improves the survival of relapsed/refractory AML patients

371 R/rAML is one of the most challenging situations in hematology, with a 5-year overall 372 survival (OS) of only 10% [41]. The prognosis of elderly or unfit r/rAML patients is even 373 more disappointing [42]. Unfortunately, no specific salvage regimen has appeared as a 374 standard treatment for r/rAML [42]. CAG regimen, containing low-dose of cytarabine, Acla 375 and G-CSF, has been widely used in China and Japan for treating AML [43, 44]. It is well 376 tolerated by r/r and elderly AML patients with lower toxicity than conventional 377 chemotherapies [43-45]. To compare the efficacy of CAG to other salvage chemotherapies in 378 r/rAML, we conducted a single-center retrospective study at Ruijin hospital (Shanghai, 379 China).

380 A total of 186 r/rAML patients, treated between July 2012 and July 2022, were included 381 in the study. In this group of patients, fit patients with *de novo* AML often received Ida in 382 combination with cytarabine (IA) rather than Daun or Doxo for first-line therapy, as Ida is 383 more effective for induction therapy in AML [46, 47]. However, all three anthracyclines are 384 cardiotoxic [48]. Among the patients who developed refractory and relapse after primary IA treatment for *de novo* disease, 66 patients received CAG regimen (2nd-line CAG group), 67 385 received other chemotherapy regimens (2nd-line others group), and 34 received emerging 386 target therapy regimen venetoclax + azacitidine $(2^{nd}$ -line VA group) (Fig. 5A). 19 patients 387 388 who were treated with CAG for both *de novo* and r/r diseases were enrolled to illustrate that Acla does not contribute to cardiotoxicity and is compatible with extended treatment 389 (1st&2nd-line CAG group) (Fig. 5A). Notably, at Ruijin hospital, CAG is usually applied to *de* 390 391 novo AML patients with unfit conditions who are not expected to tolerate conventional 392 intensive chemotherapies. The demographic and clinical characteristics of all patients at 393 r/rAML diagnosis are summarized in supplemental Table 1. There was no significant difference between 2nd-line CAG group and any other group with respect to age, gender, 394

French-American-British type, cytogenetic risk, and frequent oncogenic mutations. Slightly more patients in the 2^{nd} -line others group were diagnosed with favorable integrated risk than in the other arms of the study.

The overall complete remission (CR) rate after induction was 74% for the 2nd-line CAG 398 group, which is significantly higher than that of the 2^{nd} -line others (37%) and the 2^{nd} -line VA 399 group (35%) (Table 1). Patients with favorable and intermediate cytogenetics or integrated 400 401 risk responded better to CAG. However, cytogenetics or integrated risk was not prognostic 402 for the other groups (Table 1). Among the patients with a favorable and intermediate risk, the complete remission rate of 2nd-line CAG was superior to that of 2nd-line others and the 2nd-403 404 line VA group (Table 1). While age is a poor prognostic factor for AML [42], no significant 405 difference was seen for CAG outcome in patients <60- and ≥ 60 -year-old. Actually, for patients ≥ 60 -year-old, 2nd-line CAG also outperformed other treatment regimens (Table S2). 406 407 No CR and major prognostic mutation associations were detected for any treatment group due to small cohort (Table S2). In terms of CR rate, compared to the 2nd-line CAG group that 408 first received IA, the 1st&2nd-line CAG group performed slightly less optimally due to unfit 409 conditions. However, this treatment protocol was not inferior to the 2nd-line others and the 410 2nd-line VA group (Table 1; Table S2), suggesting that CAG remains effective and tolerable 411 412 in unfit r/rAML patients, even after prior CAG treatments.

Since both CAG and VA therapy were well tolerated, some patients continued with these regimens for consolidation therapy and long-term maintenance. Among these were patients treated for up to 11 times with CAG without any cardiac issues, far more than other anthracyclines (Fig. S5A). This strategy was not an option for IA treatment due to accumulated cardiotoxicity and resistance. Superior CR rates and/or sustainable treatment schedule of CAG and VA translated into a more than 20% better OS as compared to 2nd-line others group (Fig. 5B,C; Fig. S5B,C). Nonetheless, event-free survival analysis indicated a

better durable response of 2nd-line CAG when compared to 2nd-line VA (Fig. 5D,E), possibly
due to the development of VA resistance [49]. Of note, the 1st&2nd-line CAG patients were
selected for the limited toxicity of this regimen due to unfit conditions, which is associated
with poor prognosis. Still, these patients achieved comparable OS as the 2nd-line CAG group
(Fig. 5B,C; Fig. S5D,E). Taken together, these findings reveal that CAG regimen can be a
superior, low-toxicity chemotherapy for r/rAML, including those with unfit conditions.

426

427 **Discussion**

Despite their devastating side effect profiles, anthracyclines including doxorubicin, 428 429 daunorubicin and idarubicin have been cornerstones of oncology treatment for over 50 years. 430 While the molecular mechanisms of action have been mostly considered the same across 431 different anthracycline analogs, clinical observations and our previous studies have indicated 432 that this does not apply to all variants [2, 3, 5, 50]. Here, we performed a comprehensive 433 analysis of clinically relevant anthracyclines against key parameters including mode of 434 action, epigenomic selectivity and clinical performance, and find individual anthracyclines 435 have substantially different pharmacological properties. In the course of our evaluation, Acla 436 stood out as it is minimally cardiotoxic and prefers lymphoid organs over solid tissues. 437 Attributing to its high therapeutic index for AML, we demonstrate that Acla can be safely 438 used in second-line therapy after initial treatment of cardiotoxic anthracyclines, leading to 439 23% higher 5-year OS for r/rAML patients.

A common feature of anthracyclines is their poisoning of TopoIIα. TopoIIα plays a role in all areas of chromosome structure, from nucleosome assembly and disassembly to chromosome condensation and segregation between daughter cells [51-53]. DSB induction mediated by the catalytic activity of TopoIIα has always been considered as the primary cytotoxic mechanism of anthracyclines [1]. However, this dogma is challenged by Acla and

other anthracycline variants whose major cytotoxic activity is chromatin damage, also known as histone eviction [54]. It has been reported that deregulation of TopoII α leads to cell death in a manner independent of its catalytic activity [55, 56]. Therefore, without poisoning TopoII α for DNA damage, depleting and redistributing TopoII α are already detrimental, as illustrated by Acla. This finding further uncovers the anti-cancer mechanism of chromatin damage caused by histone eviction.

451 While Acla was first introduced into clinic 40 years ago (it was available in Europe until 452 2004 and was never registered in the U.S.), it is surprising that the unique effects of Acla in 453 r/rAML has never been realized. Our data suggest that applying CAG therapy in r/rAML 454 patients would increase their 5-year OS by 23%. If Acla was incorporated into current AML 455 regimens, 10,000 r/rAML patients in the U.S. and Europe [57] would survive annually from 456 this off-patent and low-cost drug. The impact on pediatric oncology will be even more 457 profound, as 50% of childhood cancer patients receive high-dose anthracyclines and go on to 458 have 5- to 15-fold increased risk for heart failure compared to the general population [9]. 459 Introducing Acla in their treatment would mitigate this side effect. Considering old drugs in 460 new ways may therefore substantially – and expeditiously – improve the survival and quality 461 of life of many cancer patients, as exemplified here.

462

463 Abbreviations

Acla	Aclarubicin
AML	Acute myeloid leukemia
Amr	Amrubicin
Ara-C	Cytarabine
ATAC-seq	Assay for Transposase-Accessible Chromatin using sequencing
ATRA	Retinoic acid
CAG	cytarabine, Acla and G-CSF
CFGE	Constant-field gel electrophoresis
ChIP-seq	Chromatin immunoprecipitation followed by sequencing

CR	Complete remission
Daun	Daunorubicin
DHS	DNase I hypersensitive regions
Doxo	Doxorubicin
DSBs	DNA double-strand breaks
Epi	Epirubicin
FCS	Fetal calf serum
G-CSF	Granulocyte colony stimulating factor
GEO	Gene expression omnibus
IA	Ida in combination with cytarabine
Ida	Idarubicin
IMDM	Iscove's modified dulbecco's medium
IR	Incidence rate
OS	Overall survival
PCA	Principal component analysis
γH2AX	phosphorylation of H2AX at Ser139
r/rAML	relapsed/refractory AML
SDS	Sodium dodecyl sulfate
TopoII	Topoisomerase II

464

465 **Supplementary Information**

466 Supplementary Materials.dox includes Figures S1 to S5 and Tables S1 to S2.

467

468 **Declarations**

469 **Ethics approval and consent to participate**

470 All mouse experiments were approved by the Animal Ethics Committee of the NKI and were

471 performed according to institutional and national guidelines. The retrospective clinical study

472 was approved by the ethics committee of Ruijin Hospital, and all patients provided written

473 informed consent.

474

475 Availability of data and materials

476 The sequencing data supporting the findings of this study are available at the Gene 477 Expression Omnibus (GEO) under accession numbers GSE240443 478 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE240443). Source data are 479 provided with this paper. Clinical data are available from the corresponding authors upon reasonable request and with permission of Ruijin hospital. 480

481

482 **Competing interests**

J.N. is a shareholder in NIHM that aims to produce Acla for clinical use. The authors do notdeclare any other competing interests.

485

486 Funding

This work was supported by grants from the European Research Council (ERC) (advanced grant ERCOPE 694307) (J.N.), Dutch Cancer Society (KWF 11356) (J.N.), Institute for Chemical Immunology from NWO Gravitation (NWO 024.002.009) (J.N.), Spinoza award funded by the Ministry of Education, Culture and Science of the Netherlands (NWO 00897590) (J.N.), RIKI foundation (C.L.Z.).

492

493 **Authors' contribution**

494 Contribution: X.Q., S.Y.v.d.Z. and J.N. designed experiments. X.Q. and S.Y.v.d.Z.

495 performed experiments. O.v.T., F.L.H., and M.A.v.G. contributed to experiments. Y.Z. and

496 X.L. collected the r/rAML data. X.Q., X.L., J.L. and J.N. analyzed the clinical data. M.T. and

497 B.P. performed and analyzed ChIP-seq and ATAC-seq experiments. L.J., Y.L. and B.P. made

498 stable cell lines. J.S. performed pathological analyses. C.L.Z. contributed to the result

499 interpretation. X.Q., S.Y.v.d.Z. and J.N. wrote the manuscript, with the input of all authors.

500 All authors read and approved the final manuscript.

501

502 Acknowledgements

- 503 The authors thank the people from the Preclinical Intervention Unit of the Mouse Clinic for
- 504 Cancer and Ageing (MCCA) at NKI for their technical support performing the animal
- 505 experiments and the staff from the Experimental Animal Pathology facility at NKI for their
- service on histochemistry and immunochemistry staining; Prof. J.P. Vandenbroucke and M.
- 507 Schaapveld for help with the epidemiological assessment of clinical data; J. Sarthy and I.
- 508 Berlin for comments and critical reading of the Manuscript.
- 509

510 **References**

- Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science. 1984;226(4673):466-8.
- Pang B, Qiao X, Janssen L, Velds A, Groothuis T, Kerkhoven R, et al. Drug-induced histone eviction from
 open chromatin contributes to the chemotherapeutic effects of doxorubicin. Nature communications.
 2013;4:1908.
- Pang B, de Jong J, Qiao X, Wessels LF, Neefjes J. Chemical profiling of the genome with anti-cancer drugs
 defines target specificities. Nature chemical biology. 2015;11(7):472-80.
- Yang F, Kemp CJ, Henikoff S. Doxorubicin enhances nucleosome turnover around promoters. Curr Biol.
 2013;23(9):782-7.
- 5. Qiao X, van der Zanden SY, Wander DPA, Borras DM, Song JY, Li X, et al. Uncoupling DNA damage
 from chromatin damage to detoxify doxorubicin. Proceedings of the National Academy of Sciences of the
 United States of America. 2020;117(26):15182-92.
- 6. Girling DJ. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell
 lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working
 Party. Lancet. 1996;348(9027):563-6.
- For the second second
- Sekeres MA, Guyatt G, Abel G, Alibhai S, Altman JK, Buckstein R, et al. American Society of Hematology
 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. Blood Adv.
 2020;4(15):3528-49.

- 533 9. Armenian S, Bhatia S. Predicting and Preventing Anthracycline-Related Cardiotoxicity. Am Soc Clin Oncol
 534 Educ Book. 2018;38:3-12.
- Li Y, Tan M, Sun S, Stea E, Pang B. Targeted CRISPR activation and knockout screenings identify novel
 doxorubicin transporters. Cell Oncol (Dordr). 2023.
- 537 11. Wlodek D, Banath J, Olive PL. Comparison between pulsed-field and constant-field gel electrophoresis for
 538 measurement of DNA double-strand breaks in irradiated Chinese hamster ovary cells. International journal
 539 of radiation biology. 1991;60(5):779-90.
- van der Kant R, Fish A, Janssen L, Janssen H, Krom S, Ho N, et al. Late endosomal transport and tethering
 are coupled processes controlled by RILP and the cholesterol sensor ORP1L. J Cell Sci. 2013;126(Pt
 15):3462-74.
- 543 13. Schmidt D, Wilson MD, Spyrou C, Brown GD, Hadfield J, Odom DT. ChIP-seq: using high-throughput
 544 sequencing to discover protein-DNA interactions. Methods. 2009;48(3):240-8.
- 545 14. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012;9(4):357-9.
- 546 15. Kharchenko PV, Tolstorukov MY, Park PJ. Design and analysis of ChIP-seq experiments for DNA-binding
 547 proteins. Nat Biotechnol. 2008;26(12):1351-9.
- 548 16. Amemiya HM, Kundaje A, Boyle AP. The ENCODE Blacklist: Identification of Problematic Regions of the
 549 Genome. Scientific reports. 2019;9(1):9354.
- 17. Roadmap Epigenomics C, Kundaje A, Meuleman W, Ernst J, Bilenky M, Yen A, et al. Integrative analysis
 of 111 reference human epigenomes. Nature. 2015;518(7539):317-30.
- 18. Ross-Innes CS, Stark R, Teschendorff AE, Holmes KA, Ali HR, Dunning MJ, et al. Differential oestrogen
 receptor binding is associated with clinical outcome in breast cancer. Nature. 2012;481(7381):389-93.
- Buenrostro JD, Giresi PG, Zaba LC, Chang HY, Greenleaf WJ. Transposition of native chromatin for fast
 and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. Nat
 Methods. 2013;10(12):1213-8.
- 20. Corces MR, Trevino AE, Hamilton EG, Greenside PG, Sinnott-Armstrong NA, Vesuna S, et al. An
 improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues. Nat
 Methods. 2017;14(10):959-62.
- 21. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, et al. Model-based analysis of ChIPSeq (MACS). Genome biology. 2008;9(9):R137.
- 562 22. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, et al. Karyotypic analysis
 563 predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest
 564 Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96(13):4075-83.
- 565 23. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, et al. Diagnosis and
 566 management of acute myeloid leukemia in adults: recommendations from an international expert panel, on
 567 behalf of the European LeukemiaNet. Blood. 2010;115(3):453-74.
- 568 24. Greene RF, Collins JM, Jenkins JF, Speyer JL, Myers CE. Plasma pharmacokinetics of adriamycin and
 adriamycinol: implications for the design of in vitro experiments and treatment protocols. Cancer research.
 570 1983:43(7):3417-21.
- 571 25. Kuo LJ, Yang LX. Gamma-H2AX a novel biomarker for DNA double-strand breaks. In vivo.
 572 2008;22(3):305-9.

- 573 26. Cox J, Weinman S. Mechanisms of doxorubicin resistance in hepatocellular carcinoma. Hepat Oncol.
 574 2016;3(1):57-9.
- 575 27. Wang AH, Ughetto G, Quigley GJ, Rich A. Interactions between an anthracycline antibiotic and DNA:
 576 molecular structure of daunomycin complexed to d(CpGpTpApCpG) at 1.2-A resolution. Biochemistry.
 577 1987;26(4):1152-63.
- 578 28. Gerstein MB, Kundaje A, Hariharan M, Landt SG, Yan KK, Cheng C, et al. Architecture of the human
 579 regulatory network derived from ENCODE data. Nature. 2012;489(7414):91-100.
- 580 29. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, et al. High-resolution profiling of histone
 581 methylations in the human genome. Cell. 2007;129(4):823-37.
- 30. Alvarez F, Munoz F, Schilcher P, Imhof A, Almouzni G, Loyola A. Sequential establishment of marks on
 soluble histones H3 and H4. The Journal of biological chemistry. 2011;286(20):17714-21.
- 31. Rea S, Eisenhaber F, O'Carroll D, Strahl BD, Sun ZW, Schmid M, et al. Regulation of chromatin structure
 by site-specific histone H3 methyltransferases. Nature. 2000;406(6796):593-9.
- 586 32. Zhang M, Liang C, Chen Q, Yan H, Xu J, Zhao H, et al. Histone H2A phosphorylation recruits
 587 topoisomerase IIalpha to centromeres to safeguard genomic stability. EMBO J. 2020;39(3):e101863.
- 33. Kerpel-Fronius S, Gyergyay F, Hindy I, Decker A, Sawinsky I, Faller K, et al. Phase I-II trial of
 aclacinomycin A given in a four-consecutive-day schedule to patients with solid tumours. A South-East
 European Oncology Group (SEEOG) Study. Oncology. 1987;44(3):159-63.
- 34. Martino S, Decker DA, Hynes HE, Kresge CL. Phase II evaluation of aclacinomycin-A in advanced ovarian
 carcinoma. Investigational new drugs. 1987;5(4):373-4.
- 593 35. Johnson SA, Richardson DS. Anthracyclines in haematology: pharmacokinetics and clinical studies. Blood
 594 Rev. 1998;12(1):52-71.
- 595 36. Fujihira S, Yamamoto T, Matsumoto M, Yoshizawa K, Oishi Y, Fujii T, et al. The high incidence of atrial
 596 thrombosis in mice given doxorubicin. Toxicol Pathol. 1993;21(4):362-8.
- 597 37. Lencova-Popelova O, Jirkovsky E, Mazurova Y, Lenco J, Adamcova M, Simunek T, et al. Molecular
 598 remodeling of left and right ventricular myocardium in chronic anthracycline cardiotoxicity and post599 treatment follow up. PloS one. 2014;9(5):e96055.
- 38. Zhao S, Wu H, Xia W, Chen X, Zhu S, Zhang S, et al. Periostin expression is upregulated and associated
 with myocardial fibrosis in human failing hearts. J Cardiol. 2014;63(5):373-8.
- Guo R, Hua Y, Ren J, Bornfeldt KE, Nair S. Cardiomyocyte-specific disruption of Cathepsin K protects
 against doxorubicin-induced cardiotoxicity. Cell Death Dis. 2018;9(6):692.
- 40. Lotrionte M, Biondi-Zoccai G, Abbate A, Lanzetta G, D'Ascenzo F, Malavasi V, et al. Review and metaanalysis of incidence and clinical predictors of anthracycline cardiotoxicity. The American journal of
 cardiology. 2013;112(12):1980-4.
- 607 41. Ganzel C, Sun Z, Cripe LD, Fernandez HF, Douer D, Rowe JM, et al. Very poor long-term survival in past
 608 and more recent studies for relapsed AML patients: The ECOG-ACRIN experience. Am J Hematol.
 609 2018;93(8):1074-81.
- 42. Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management
 of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-
- 612 47.

43. Yamada K, Furusawa S, Saito K, Waga K, Koike T, Arimura H, et al. Concurrent use of granulocyte

- colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute
 myelogenous leukemia: a pilot study. Leukemia. 1995;9(1):10-4.
- 44. Wei G, Ni W, Chiao JW, Cai Z, Huang H, Liu D. A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF)
- regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome.Journal of hematology & oncology. 2011;4:46.
- 45. Jin J, Chen J, Suo S, Qian W, Meng H, Mai W, et al. Low-dose cytarabine, aclarubicin and granulocyte
 colony-stimulating factor priming regimen versus idarubicin plus cytarabine regimen as induction therapy
 for older patients with acute myeloid leukemia. Leuk Lymphoma. 2015;56(6):1691-7.
- 622 46. Owattanapanich W, Owattanapanich N, Kungwankiattichai S, Ungprasert P, Ruchutrakool T. Efficacy and
 623 Toxicity of Idarubicin Versus High-dose Daunorubicin for Induction Chemotherapy in Adult Acute
 624 Myeloid Leukemia: A Systematic Review and Meta-analysis. Clin Lymphoma Myeloma Leuk.
 625 2018;18(12):814-21 e3.
- 47. Wang H, Xiao X, Xiao Q, Lu Y, Wu Y. The efficacy and safety of daunorubicin versus idarubicin
 combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized
 clinical trials. Medicine (Baltimore). 2020;99(24):e20094.
- 48. McGowan JV, Chung R, Maulik A, Piotrowska I, Walker JM, Yellon DM. Anthracycline Chemotherapy
 and Cardiotoxicity. Cardiovasc Drugs Ther. 2017;31(1):63-75.
- 49. DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S, Brown FC, et al. Molecular patterns of
 response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood.
 2020;135(11):791-803.
- 50. Wu JF, Zhou JJ, Li XA, Hu LH, Wen ML. The safety and efficacy of amrubicin in the treatment of
 previously untreated extensive-disease small-cell lung cancer: a meta-analysis. Onco Targets Ther.
 2019;12:5135-42.
- 51. DiNardo S, Voelkel K, Sternglanz R. DNA topoisomerase II mutant of Saccharomyces cerevisiae:
 topoisomerase II is required for segregation of daughter molecules at the termination of DNA replication.
 Proceedings of the National Academy of Sciences of the United States of America. 1984;81(9):2616-20.
- 52. Uemura T, Yanagida M. Isolation of type I and II DNA topoisomerase mutants from fission yeast: single
 and double mutants show different phenotypes in cell growth and chromatin organization. EMBO J.
 1984;3(8):1737-44.
- 53. Uemura T, Ohkura H, Adachi Y, Morino K, Shiozaki K, Yanagida M. DNA topoisomerase II is required for
 condensation and separation of mitotic chromosomes in S. pombe. Cell. 1987;50(6):917-25.
- 54. Wander DPA, van der Zanden SY, Vriends MBL, van Veen BC, Vlaming JGC, Bruyning T, et al. Synthetic
 (N,N-Dimethyl)doxorubicin Glycosyl Diastereomers to Dissect Modes of Action of Anthracycline
 Anticancer Drugs. The Journal of organic chemistry. 2021;86(8):5757-70.
- 55. Holm C, Goto T, Wang JC, Botstein D. DNA topoisomerase II is required at the time of mitosis in yeast.
 Cell. 1985;41(2):553-63.
- 56. McPherson JP, Goldenberg GJ. Induction of apoptosis by deregulated expression of DNA topoisomerase
 IIalpha. Cancer research. 1998;58(20):4519-24.

- 652 57. Seattle IfHMaEI, United States. Global Burden of Disease Study 2019 Results. Global Burden of Disease
- 653 Collaborative Network. 2020: Available from <u>https://vizhub.healthdata.org/gbd-results/</u>.

654

Clinical outcome Complete remission		2 nd -line CAG (n=65)		2 nd -line Others		2 nd -line VA		1 st &2 nd -line CAG			
				=51)	P value	(n=31)		P value	(n:	=17)	P value
Overall	48/65	(74%)	19/51	(37%)	0.0001†	11/31	(35%)	0.0006†	10/17	(59%)	0.24331
Complete remission		0.0279‡			>0.9999‡			>0.9999			0.5500
Favourable and intermediate cytogenetics	40/50	(80%)	17/46	(37%)	<0.0001†	8/23	(35%)	0.0004†	8/13	(62%)	0.2704
Unfavourable cytogenetics	5/11	(45%)	2/5	(40%)	>0.99991	2/5	(40%)	>0.9999†	1/3	(33%)	>0.9999
Unknown cytogenetics	3/4	(75%)	0/0	(NA)	>0.9999	1/2	(50%)	>0.9999†	1/1	(100%)	>0.9999
Complete remission		0.0087‡			>0.9999‡			0.2553‡			>0.9999
Favourable and intermediate integrated risk	34/40	(85%)	12/32	(38%)	<0.0001†	5/19	(26%)	<0.0001†	6/10	(60%)	0.0966
Unfavourable integrated risk	9/18	(50%)	6/16	(38%)	0.7055†	6/12	(50%)	>0.9999†	3/5	(60%)	>0.9999
Unknown integrated risk	5/7	(71%)	1/3	(33%)	0.5000†	0/0	(NA)	>0.99991	1/2	(50%)	>0.9999

655

Table 1. Treatment outcomes of r/rAML patients. CAG: cytarabin, aclarubicin, G-CSF; IA: idarubicin,
cytarabine; VA: venetoclax, azacitidine; Others: chemotherapy regimens other than CAG. Data are n/N (%). †
Fisher's exact test between the indicated group and 2nd-line CAG group. ‡ Fisher's exact test within group.

659

660 Figure 1. Acla differs from other anthracyclines in mechanisms of action and cross-resistance. (A) 661 Structures of anthracyclines used in this study. Chemical moieties divergent from Doxo are depicted in red. (B) 662 DNA damage examined by γ H2AX Western blot. (C) Quantification of the γ H2AX signal normalized to β -663 actin. Data are mean \pm SEM; n = 4 biological replicates; Student's *t*-test. (D) DSBs analyzed by CFGE. (E) 664 Quantification of relative broken DNA in (D). Data are mean $\Box \pm \Box$ SEM; $n \Box = \Box 4$ biological replicates; Student's 665 t-test. (F) Histone eviction revealed by cell fractionation assay in K562-eGFP-H2B cells. N, nuclear fraction; C, 666 cytosolic fraction. Calnexin and Lamin B1 are the loading control of each fraction. (G) The distribution of 667 eGFP-H2B was quantified for both compartments. Data are mean \pm SD; $n\Box = \Box 4$ biological replicates; two-way 668 ANOVA. (H) IC₅₀ of each anthracycline in different leukemia cell lines. (I, J) Cell viability of parental K562 669 cells and ABCB1-overexpressing K562 cells upon Doxo (I) and Acla (J) treatment. Data are mean ± SD; 670 $n \equiv \exists 3$ biological replicates; two-way ANOVA. (K) Relative IC₅₀ folds of each condition compared to that of 671 Doxo in parental K562 cells. Data are mean $\Box \pm \Box$ SEM; $n \Box = \Box 3$ biological replicates; Student's *t*-test. *P < 0.05, 672 ***P* < 0.01, ****P* < 0.001, and *****P* < 0.0001; n.s., not significant.

673

Figure 2. Epigenetic selectivity of TopoIIα redistribution and histone eviction of anthracyclines. (A)
Illustration of drug-specific TopoIIα redistribution revealed by ChIP-seq. (B) Principal component analysis
(PCA) of TopoIIα ChIP-seq data. Two independent biological replicates were included for each condition. (C)
Heatmap of TopoIIα peak abundance associated with specific histone features derived from Roadmap
Epigenomics Project. (D) Illustration of drug-specific accessible chromatin regions revealed by ATAC-seq. (E)

679 PCA analysis of ATAC-seq data. Two independent biological replicates were included for each condition. (F) 680 Heatmap of ATAC peak abundance associated with specific histone. (G) Density plots showing the accessible 681 and inaccessible TopoII α regions, and TopoII α -excluded accessible regions surrounding ±2 \Box kb from the center 682 of the detected peaks in the untreated K562 cells. (H) The abundance of each category in different conditions.

683

Figure 3. Bio-distribution of clinically-used anthracyclines in mice. (A) Drug bio-distribution was determined 4 hours after i.v. injection of indicated drug at 5 mg/kg. Data are represented as mean $\Box \pm$ SD from 5 mice per group. Student's *t*-test. (B) Representative microscopic images of γ H2AX IHC staining of the hearts. Scale bars, 100 µm. Quantification is represented as mean $\Box \pm \Box$ SD, n = 5, Mann-Whitney test. *P < 0.05, **P <0.01, ***P < 0.001, and ****P < 0.0001; n.s., not significant.

689

690 Figure 4. Acla is safe and well tolerated following Doxo treatment. (A) Wild-type FVB mice were i.v. 691 injected with Doxo (D), Acla (A), or saline (C) as indicated. (B E) Representative microscopic images of the 692 left atrium (LA) of heart. Lesions caused by Doxo treatment represent as impairment of the wall, thrombosis, 693 inflammation, fibrosis/calcification, and disappearing of the lumen of atrium (filled by a large thrombus). Scale 694 bars, 500 μ m. (F \square H) Quantification of the indicated IHC staining in LA. Data are mean $\square \pm \square$ SEM, Mann-695 Whitney test. (I) Animal survival is plotted in Kaplan-Meier curves. Log-rank test. (J) Cumulative incidence of 696 cardiotoxicity. Fisher's exact test. (K) Incidence rate of cardiotoxicity. Two-way ANOVA with repeated 697 measures, two-sided. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001; n.s., not significant.

698

699 Figure 5. CAG is effective in treating r/rAML patients. (A) The therapy overview of Ruijin AML cohort. 700 CAG: cytarabin, aclarubicin, G-CSF; IA: idarubicin, cytarabine; VA: venetoclax, azacitidine; Others: 701 chemotherapy regimens other than CAG. (B) Overall survival of the r/rAML patients from the start of r/rAML 702 induction treatment to the date of death. Log-rank test. (C) The statistical analysis of OS of r/rAML patients at 2 703 years. Data are n/N (%), * compared with 2nd-line CAG group, † Fisher's exact test, ‡ Log-rank test, § Mantel-704 Haenszel test, # compared with 2nd-line CAG patients with favorable and intermediate cytogenetics. (D) Event-705 free survival of the r/rAML patients from the start of r/rAML induction treatment to the date of 706 relapse/refractory/death. (E) The statistical analysis of EFS of r/rAML patients at 2 years. Data are n/N (%), * compared with 2nd-line CAG group, † Fisher's exact test, ‡ Log-rank test, § Mantel-Haenszel test, # compared 707 708 with 2nd-line CAG patients with favorable and intermediate cytogenetics.

Figure 1



Figure 2 A



Figure 3





Time post treatment start (weeks)

Time post treatment start (weeks)

Figure 5 A





С

OS of r/rAML at 2 years	2 nd -line CAG	2 nd -line Others	2 nd -line VA	1 st &2 nd -line CAG	
Overall	P value#	P value*	P value*	P value*	
Survival	36/63 (57%)	21/67 (31%) 0.0045†	17/33 (52%) 0.6681†	10/19 (53%) 0.7952†	
Median time (month)	NA	9.6 0.0016 ‡	15.4 0.2079‡	NA 0.6615‡	
Hazard Ratio (95% CI)		2.109 (1.327 – 3.353)§	1.535 (0.7880 – 2.988)§	1.193 (0.5414 – 2.629)§	
Favourable and intermediate cytoge	enetics				
Survival	29/48 (60%)	17/58 (29%) 0.0017†	15/27 (56%) 0.8078†	7/14 (50%) 0.5475†	
Median time (month)	NA	9.2 0.0004‡	NA 0.2901‡	15.1 0.4251‡	
Hazard Ratio (95% CI)		2.538 (1.522 – 4.232)§	1.521 (0.6995 – 3.306)§	1.474 (0.5683 – 3.822)§	
Unfavourable cytogenetics					
Survival	4/11 (36%) 0.1873†	3/7 (43%) >0.9999†	1/5 (20%) >0.9999†	1/3 (33%) >0.9999†	
Median time (month)	9.3 0.0698‡	10.2 0.7269‡	4.8 0.4112‡	5 0.6809‡	
Hazard Ratio (95% CI)	2.758 (0.9213 – 8.255)§	0.8071 (0.2424 – 2.687)§	1.769 (0.4538 – 6.894)§	1.441 (0.2525 – 8.225)§	

Ε





	EFS of r/rAML at 2 years	2 nd -line	CAG	2 nd -line VA				
	Overall		P value#		P value*			
	Survival	29/63 (46%)		9/34 (26%)	0.0813†			
	Median time (month)	15.2		3.35	0.0108‡			
	Hazard Ratio (95% CI)			2.121 (1.190	– 3.782)§			
	avourable and intermediate cytogenetics							
	Survival	23/48 (48%)		8/27 (30%)	0.1478†			
	Median time (month)	22.8		3.6	0.0166‡			
	Hazard Ratio (95% CI)			2.273 (1.161	- 4.449)§			
	Unfavourable cytogenetics							
	Survival	3/11 (27%)	0.3162†	1/5 (20%)	>0.9999†			
	Median time (month)	4.3	0.0684‡	1.7	0.7396‡			
	Hazard Ratio (95% CI)	2.543 (0.9318	3 – 6.942)§	1.212 (0.349	3 – 4.207)§			

Diverging the anthracycline class of anti-cancer drugs for superior survival of AML patients



Considering individual anthracyclines as different drugs can markedly improve survival of AML patients while reducing the toxic side-effects.